Upon the FDA approval of psychedelic medicine for psychiatric indications—such as MDMA for post-traumatic stress disorder or psilocybin for depression—psychiatric pharmacists in particular and all pharmacists generally, will play a pivotal role in the psychedelic medicine market in the US.